What is ResMed's stock symbol?
ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."
How often does ResMed pay dividends? What is the dividend yield for ResMed?
ResMed announced a quarterly dividend on Monday, January 23rd. Stockholders of record on Thursday, February 9th will be paid a dividend of $0.33 per share on Thursday, March 16th. This represents a $1.32 annualized dividend and a dividend yield of 1.83%. The ex-dividend date is Tuesday, February 7th.
Where is ResMed's stock going? Where will ResMed's stock price be in 2017?
11 brokers have issued 1 year price objectives for ResMed's shares. Their predictions range from $50.00 to $72.00. On average, they expect ResMed's share price to reach $60.88 in the next year.
When will ResMed announce their earnings?
ResMed is scheduled to release their next quarterly earnings announcement on Monday, April, 24th 2017.
What are analysts saying about ResMed stock?
Here are some recent quotes from research analysts about ResMed stock:
According to Zacks Investment Research, "ResMed reported an impressive second quarter of fiscal 2017, with both earnings and revenues ahead of the respective Zacks Consensus Estimate. The top line growth was driven primarily by a solid performance in the U.S. Share price trend over the past three months that traded significantly above the broader Medical Products Industry, also reflects this bullish show. Moreover ResMed’s product launches and new strategies to capture SDB market also boosted the earnings. On the flip side, even though the company's mask sales in the combined EMEA and APAC regions declined year-over-year, it registered a growth in U.S. Its rising operating expenses is also a matter of concern. However, challenges like rising operating costs, currency headwinds competitive bidding and reimbursement issues continue to plague the stock." (2/21/2017)
Needham & Company LLC analysts commented, "RMD’s revenue and EPS beat consensus in F2Q17. RMD’s gross margin was lower than expected as price declines and mix (both product and geographic) were partially offset by manufacturing efficiencies and the Brightree acquisition. However, this was offset by lower than expected SG&A and R&D expense and RMD’s operating margin beat our estimate. Despite the headline results, this wasn’t a clean quarter in our view since flow generator growth of 17% CC was helped by a few temporary factors (the AirStart liquidation and some stocking orders in China), mask growth was disappointing at 2% CC, and gross margin declined significantly on an organic basis." (1/24/2017)
Canaccord Genuity analysts commented, "We like the direction RMD is taking with the Brightree acquisition, toward the higher margin and faster-growing informatics/software space, which is complementary to, and could augment (long-term) the small but burgeoning, ventilator-focused COPD market and more mature, price-deflationary OSA market." (2/23/2016)
Who owns ResMed stock?
ResMed's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (3.56%), State Street Corp (3.18%), FMR LLC (2.78%), Matthews International Capital Management LLC (0.77%), Congress Asset Management Co. MA (0.61%) and Janus Capital Management LLC (0.51%). Company insiders that own ResMed stock include Anne Reiser, Brett Sandercock, Christopher G Roberts, David Pendarvis, Donald Darkin, Franz Kozich, Gary W Pace, James Hollingshead, John P Wareham, Michael J Farrell, Peter C Farrell, Richard Sulpizio, Robert Andrew Douglas, Ronald R Taylor and Warren Russell Hawkins.
Who sold ResMed stock? Who is selling ResMed stock?
ResMed's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Columbia Wanger Asset Management LLC, FMR LLC, Two Sigma Investments LP, Baillie Gifford & Co., AQR Capital Management LLC, State Street Corp and Nicholas Co. Inc. WI. Company insiders that have sold ResMed stock in the last year include Anne Reiser, Brett Sandercock, Christopher G Roberts, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Michael J Farrell, Peter C Farrell, Richard Sulpizio and Ronald R Taylor.
Who bought ResMed stock? Who is buying ResMed stock?
ResMed's stock was acquired by a variety of institutional investors in the last quarter, including Congress Asset Management Co. MA, Russell Investments Group Ltd., Janus Capital Management LLC, Asset Management One Co. Ltd., Shelton Capital Management, Motley Fool Wealth Management LLC, Tandem Investment Advisors Inc. and Marshall Wace LLP. Company insiders that have bought ResMed stock in the last two years include Franz Kozich, Ronald R Taylor and Warren Russell Hawkins.
How do I buy ResMed stock?
Shares of ResMed can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of ResMed stock cost?
One share of ResMed stock can currently be purchased for approximately $72.21.